BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35751420)

  • 1. Special issue "The advance of solid tumor research in China": 68Ga-PSMA-11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma.
    Li Y; Zheng R; Zhang Y; Huang C; Tian L; Liu R; Liu Y; Zhang Z; Han H; Zhou F; He L; Dong P
    Int J Cancer; 2023 Jan; 152(1):42-50. PubMed ID: 35751420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential role of
    Aggarwal P; Singh H; Das CK; Mavuduru RS; Kakkar N; Lal A; Gorsi U; Kumar R; Mittal BR
    Eur J Radiol; 2024 Jan; 170():111218. PubMed ID: 38007857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [
    Yin Y; Campbell SP; Markowski MC; Pierorazio PM; Pomper MG; Allaf ME; Rowe SP; Gorin MA
    Mol Imaging Biol; 2019 Jun; 21(3):567-573. PubMed ID: 30218388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of
    Raveenthiran S; Esler R; Yaxley J; Kyle S
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2280-2288. PubMed ID: 31332498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [
    Lin R; Wang C; Chen S; Lin T; Cai H; Chen S; Yang Y; Zhang J; Xu F; Zhang J; Chen X; Zang J; Miao W
    Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):535-547. PubMed ID: 37728667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Head-to-head comparisons of enhanced CT, 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in identifying adverse pathology of clear-cell renal cell carcinoma: a prospective study.
    Chen SH; Lin BH; Chen SM; Qiu QR; Ruan ZT; Chen ZJ; Wei Y; Zheng QS; Xue XY; Miao WB; Xu N
    Int Braz J Urol; 2023; 49(6):716-731. PubMed ID: 37624658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Prognostic Value of
    Gasparro D; Scarlattei M; Silini EM; Migliari S; Baldari G; Cervati V; Graziani T; Campanini N; Maestroni U; Ruffini L
    Diagnostics (Basel); 2023 Sep; 13(19):. PubMed ID: 37835825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
    Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
    Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of PSMA-targeted PET-CT in renal cell carcinoma: a systematic review and meta-analysis.
    Singhal T; Singh P; Parida GK; Agrawal K
    Ann Nucl Med; 2024 Mar; 38(3):176-187. PubMed ID: 38340144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of [
    Uprimny C; Svirydenka A; Fritz J; Kroiss AS; Nilica B; Decristoforo C; Haubner R; von Guggenberg E; Buxbaum S; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How accurate is
    Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
    Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer.
    Evangelista L; Basso U; Maruzzo M; Novara G
    Eur Urol Focus; 2020 Jan; 6(1):146-150. PubMed ID: 30120074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT).
    Tariq A; McGeorge S; Pearce A; Rhee H; Wood S; Kyle S; Marsh P; Raveenthiran S; Wong D; McBean R; Westera J; Dunglison N; Esler R; Navaratnam A; Yaxley J; Thomas P; Pattison DA; Roberts MJ
    Urol Oncol; 2022 Jun; 40(6):276.e1-276.e9. PubMed ID: 35466037
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Parghane RV; Basu S
    J Nucl Med Technol; 2023 Sep; 51(3):261-262. PubMed ID: 36041875
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head-to-head comparison of [
    Wang G; Li L; Wang J; Zang J; Chen J; Xiao Y; Fan X; Zhu L; Kung HF; Zhu Z
    Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1499-1509. PubMed ID: 36600099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic potential of PET/CT using a
    Sawicki LM; Buchbender C; Boos J; Giessing M; Ermert J; Antke C; Antoch G; Hautzel H
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):102-107. PubMed ID: 26996777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary lymph-node staging with
    Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
    Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [
    Meng L; Zhang S; Gao J; Xu Q; Fu Y; Zhou YH; Wang F; Guo H
    Eur Radiol; 2022 Sep; 32(9):6545-6553. PubMed ID: 35357538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.